单株抗体联合研究及授权协议（2019-2024）

Monoclonal Antibody Collaboration and Licensing Deals 2019-2024

出版日期: 2024年11月01日 | 出版商:

Current Partnering | 英文 350+ Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

本报告研究了单株抗体合作和授权协议，详细瞭解和分析公司如何以及为何签订单株抗体协议。

介绍
过去几年单株抗体合约
最活跃的单株抗体承包商
单株抗体合约：依合约类型
单株抗体合约：按治疗领域
单株抗体合约：依行业分类
单株抗体协议条款与条件
- 单株抗体合约总金额
- 单株抗体合约预付款
- 单株抗体合约的里程碑付款
- 单株抗体特许权使用费率

第3章主要单株抗体合约

介绍
按价值排名最高的单株抗体合约

第 4 章：最活跃的单株抗体承包商

介绍
最活跃的单株抗体承包商
最活跃的单株抗体承包商概况

第5章单株抗体合约名录

介绍
单株抗体合约目录

第6章单株抗体合约：依技术类型

合约目录
合约目录 - 单株抗体合约：按公司 (AZ)
合约目录 - 单株抗体合约：依合约类型
合约目录 - 单株抗体合约：依治疗领域
定义合约类型
关于Biopharma Research Ltd
目前的合作伙伴
目前协议
目前合作伙伴最近报告的标题

简介目录

Product Code: CP21131

Monoclonal Antibody Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the monoclonal antibody deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of monoclonal antibody deals from 2019 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 639 monoclonal antibody deals announced since 2019 including financial terms where available including links to online deal records of actual monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of monoclonal antibody dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in monoclonal antibody dealmaking since 2019.

Chapter 3 provides an overview of the leading monoclonal antibody deals since 2019. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of monoclonal antibody deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of monoclonal antibody deals signed and announced since Jan 2019, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2019. The chapter is organized by specific monoclonal antibody technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in monoclonal antibody deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Monoclonal Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2019
Browse monoclonal antibody collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, deal type and therapy area
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Monoclonal Antibody Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of monoclonal antibody trends and structure of deals entered into by leading biopharma companies worldwide.

Monoclonal Antibody Collaboration and Licensing Deals includes:

Trends in monoclonal antibody dealmaking in the biopharma industry
Directory of monoclonal antibody deal records covering pharmaceutical and biotechnology
The leading monoclonal antibody deals by value
Most active monoclonal antibody licensing dealmakers
Monoclonal Antibody Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in monoclonal antibody dealmaking

2.1. Introduction
2.2. Monoclonal antibody deals over the years
2.3. Most active monoclonal antibody dealmakers
2.4. Monoclonal antibody deals by deal type
2.5. Monoclonal antibody deals by therapy area
2.6. Monoclonal antibody deals by industry sector
2.7. Deal terms for monoclonal antibody deals
- 2.7.1 Monoclonal antibody deals headline values
- 2.7.2 Monoclonal antibody deal upfront payments
- 2.7.3 Monoclonal antibody deal milestone payments
- 2.7.4 Monoclonal antibody royalty rates